Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2022 16:35 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data...
January 11, 2022 06:00 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies ...
January 10, 2022 16:30 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...
January 04, 2022 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
December 12, 2021 09:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs

Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional...
November 08, 2021 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates

Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million SEATTLE, Nov. 08, 2021 (GLOBE...
November 04, 2021 09:07 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
October 19, 2021 09:00 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs

Agreement combines Beam’s gene editing technology with Sana’s ex vivo platform SEATTLE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and...
September 07, 2021 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
August 04, 2021 16:05 ET | Source: Sana Biotechnology, Inc

Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates

Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression at ISSCR 2021 Entered long-term lease to establish manufacturing...